MiNK Therapeutics, Inc.
INKT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 41.5% and free cash flow fell 32.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow INKT
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
13.36 | 4.58 | 3.37 | 19.64 | 38.89 | 2.69 | 0.30 |
Other current assets |
0.21 | 0.16 | 0.18 | 0.47 | 0.74 | 0.91 | 0.53 |
Total current assets |
13.85 | 4.99 | 3.60 | 20.40 | 39.63 | 4.10 | 0.92 |
Property, Plant, Equpment (Net) |
0.39 | 0.73 | 0.95 | 1.07 | 0.61 | 0.46 | 0.39 |
Total non-current assets |
0.39 | 0.73 | 0.95 | 1.07 | 0.61 | 0.46 | 0.39 |
Total Assets |
14.24 | 5.72 | 4.55 | 21.47 | 40.24 | 4.56 | 1.31 |
Notes Payable |
5.18 | — | — | — | — | — | — |
Accounts Payable |
3.43 | 2.73 | 3.91 | 5.82 | 3.00 | 3.14 | 2.46 |
Accrued Expenses |
1.58 | 1.87 | 5.04 | 4.24 | 1.76 | 1.86 | 2.60 |
Current Revenue (Deferred) |
— | — | — | — | — | — | 0.19 |
Other current liabilities |
2.85 | 2.36 | 2.45 | 2.62 | 5.76 | 5.69 | 4.96 |
Total current liabilities |
13.03 | 6.96 | 11.40 | 12.68 | 16.47 | 14.22 | 7.42 |
Long Term Debt (Total) |
— | 4.92 | — | — | — | 43.82 | 26.79 |
Non-current Liabilities (Other) |
15.44 | 13.42 | 11.21 | 9.19 | — | 0.38 | 3.43 |
Total non-current liabilities |
15.44 | 18.35 | 11.21 | 9.19 | — | 44.21 | 30.22 |
Total liabilities |
28.47 | 25.31 | 22.61 | 21.87 | 16.47 | 58.43 | 37.64 |
Additional Paid In Capital |
143.17 | 125.23 | 115.77 | 110.83 | 107.35 | 0.38 | 0.29 |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Retained Earnings |
(156.68) | (144.18) | (133.40) | (110.94) | (82.95) | (52.74) | (36.50) |
Common Equity (Total) |
(14.23) | (19.59) | (18.06) | (0.40) | 23.78 | (53.87) | (36.33) |
Shareholders Equity (Total) |
(14.23) | (19.59) | (18.06) | (0.40) | 23.78 | (53.87) | (36.33) |
Shareholders Equity and Liabilities (Total) |
14.24 | 5.72 | 4.55 | 21.47 | 40.24 | 4.56 | 1.31 |
Shares (Common) |
4.71 | 3.96 | 3.46 | 3.39 | 3.35 | 2.42 | 2.41 |
Shareholders Equity (Tangible) |
(14.23) | (19.59) | (18.06) | (0.40) | 23.78 | (53.87) | (36.33) |
Net Debt |
(13.36) | 0.35 | (3.37) | (19.64) | (38.89) | 41.13 | 26.49 |
Total Debt |
— | 4.92 | — | — | — | 43.82 | 26.79 |